Considerations for the Use of rHuEpo Outside the Setting of Uremia
| HIV-related anemia4-150 |
| Chemotherapy-induced anemia4-151 |
| Perisurgical setting‡ |
| Autologous blood collectionρ |
| Anemia of prematurity |
| Anemia of cancer |
| Anemia associated with MM |
| Anemia associated with non-Hodgkin lymphoma |
| Acceleration of erythroid repopulation after allogeneic BMT |
| Hyporegenerative anemia in patients undergoing organ transplantation and receiving cyclosporin A to avoid rejection |
| Adjuvant for phlebotomy |
| Anemia of rheumatoid arthritis |
| Anemia of inflammatory bowel disease |
| MDS |
| Pure RBC aplasia |
| Induction of Hb F synthesis in sickle cell anemia and thalassemia |
| Orthostatic hypotension |
| HIV-related anemia4-150 |
| Chemotherapy-induced anemia4-151 |
| Perisurgical setting‡ |
| Autologous blood collectionρ |
| Anemia of prematurity |
| Anemia of cancer |
| Anemia associated with MM |
| Anemia associated with non-Hodgkin lymphoma |
| Acceleration of erythroid repopulation after allogeneic BMT |
| Hyporegenerative anemia in patients undergoing organ transplantation and receiving cyclosporin A to avoid rejection |
| Adjuvant for phlebotomy |
| Anemia of rheumatoid arthritis |
| Anemia of inflammatory bowel disease |
| MDS |
| Pure RBC aplasia |
| Induction of Hb F synthesis in sickle cell anemia and thalassemia |
| Orthostatic hypotension |
Considerations are listed in decreasing order of evidence for their effectiveness. Approved indications are listed first. Indications based on uncontrolled studies are listed last.
Approved in the United States for treatment of anemia induced by AZT therapy in HIV-infected patients with endogenous Epo levels less than 500 mU/mL.
Approved in the United States for anemia induced by chemotherapy of nonmyeloid malignancies.
Approved in the United States for reduction of allogeneic blood transfusion in surgery patients. Indication limited to anemic patients (Hb > 10 and <13 g/dL) undergoing elective surgery and patients at high risk for significant perioperative blood loss. Nonindicated for anemic patients willing to donate autologous blood or undergoing cardiac or vascular surgery.
ρ Approved in some European countries.